Zoetis Q3 adjusted EPS $1.70 (+8%); revenue $2.4B (+4% organic); FY guidance narrowed

Zoetis Inc.

2025-Q3 EPS reported $4.65 revenue$7,080,000,000

Q3 revenue $2.4B (+1% reported; +4% organic operational); net income $721M, $1.63 diluted EPS (+9% YoY).
Adjusted net income $754M, $1.70 adjusted diluted EPS (+8% reported; +12% organic operational).
U.S. segment revenue $1.3B (-2% reported, +3% organic); International $1.1B (+3% reported, +6% organic).
Updated FY2025 revenue guidance $9.400-9.475B (5.5-6.5% organic growth); adjusted EPS $6.30-6.40 maintained.
Regulatory milestones: Lenivia approved in Canada/EU for canine OA pain; Portela approved in EU for feline OA.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.